Kornimate/medical-research-clean huggingface dataset:
genetic variants of annexin a2 and cryptogenic stroke

Conditions: Annexin A2; Stroke; Genetic Variants of Host; Fibrinolysis

Summary: stroke is the third most common cause of death in developed countries. various mechanisms of ischemic stroke exist. however, in young population, in a third of cases, the cause of a stroke cannot be determined despite an extensive evaluation. many studies have highlighted the link between stroke and fibrinolysis. genetic variants of tpa and pai-1 genes have been suggested to be the risk factors for stroke. anxa2 plays a pivotal role in plasmin generation and fibrinolysis. several studies showed the role of anxa2 and s100a10 subunits in regulation of fibrinolysis in vivo. recently, the efficacy of recombinant anxa2 for fibrinolytic therapy in a rat embolic stroke has been demonstrated. some single nucleotide polymorphisms in anxa2 gene could be associated with increased risk of stroke in sickle cell disease. therefore, these data invite us to test hypothesis that genetic variants of anxa2 gene could be associated with ischemic stroke.


Eligibility criteria:
inclusion criteria: * completed ischemic stroke defined as a rapidly developing focal neurologic deficit with no apparent cause other than a vascular origin that persisted beyond 24 hours in surviving patients * age from 18 years old exclusion criteria: * transient ischemic attack * pregnancy

Keywords: annexin a2 stroke genetic variants fibrinolysis
switched memory b-cells as a marker for humoral immune system recovery in patients with secondary antibody deficiency due to hematological malignancies

Conditions: Secondary Antibody Deficiency

Summary: current treatment for patients with secondary antibody deficiency (sad) is immunoglobulin replacement therapy (igrt). there are currently no clinical guidelines for igrt discontinuation in patients with sad. this study will examine the igrt discontinuation success rate and igrt discontinuation rate in patients.

immunoglobulin replacement therapy (igrt) is a mainstay treatment for sad and has been shown to reduce the risk of infection and increase quality of life in patients with sad. current guidelines recommend that patients with severe hypogammaglobulinemia (igg \<4 g/l) or patients with a history of recurrent or severe infections should be offered igrt, which can be administered intravenously on a monthly basis or more frequently by subcutaneous infusions. there are currently no clinical guidelines for igrt discontinuation. although research conducted at the ottawa hospital indicates successful discontinuation of igrt, clinicians need a tool to predict the recovery of humoral immunity and the risk of infection in these patients in order to determine whether igrt may be safely discontinued.

Eligibility criteria:
inclusion criteria: 1. history of leukemia, lymphoma, or plasma cell disease 2. receiving igrt for sad for at least 12 months 3. over 18 years of age 4. able to provide informed consent 5. able to speak english or french 6. available for ongoing follow-up as required exclusion criteria: 1. receiving chemotherapy or immune-oncology treatment during the study period 2. severe infection within the last 6 months 3. pregnancy
a prospective clinical study to validate a preoperative risk scoring model for lnm in gc patients

Conditions: Predictive Cancer Model; Gastric Cancer; Lymph Node Metastasis

Summary: in our prior research, a risk scoring model for the occurrence of lymph node metastasis in patients who underwent radical gastrectomy for gastric cancer was established. to further validate this scoring model, a prospective study has been designed with the aim of prospectively assessing the model's clinical applicability.

the study was a single-centre, prospective study. data prospectively accrued were employed to evaluate the concordance between observed patient outcomes, with respect to lymph node metastasis status post-curative gastrectomy, and the prognostications tendered by the established risk scoring model, thereby appraising the model's clinical applicability and validity.

Eligibility criteria:
inclusion criteria: 1. primary gastric adenocarcinoma; 2. curative surgery (with r0 resection, excluding palliative surgery and cases with distant metastasis). exclusion criteria: 1. patients with autoimmune diseases, inflammation, or hematological disorders; 2. patients with a history of or concurrent other cancers; 3. presence of active infection and inflammation (based on wbc count, patients with count of 10×10\^9 or higher should be evaluated through medical record examination for the presence of infection); 4. active bleeding (as determined by endoscopic ultrasound and hgb ≤ 90); 5. post neoadjuvant radiotherapy or chemotherapy; 6. history of blood transfusion, corticosteroid use, or leukocyte-stimulating medications within the past month prior to blood draw; 7. incomplete clinical and pathological data.
to evaluate the effect of mcs® in prostate cancer prevention

Conditions: Prostate Cancer

Summary: to evaluate the effect of mcs® compared with placebo in reducing the risk of biopsy-detectable prostate cancer in high-risk subjects after 104 weeks (24 months) of treatment.


Eligibility criteria:
inclusion criteria: 1. high-risk subjects of prostate cancer. 2. male subject with age from 50 to 75 years old. 3. subject is able to understand and willing to comply with the study procedures and has signed the informed consent form (icf). exclusion criteria: 1. subjects who are or will be taking long-term hormonal agents that may affect the normal physiology of sex hormone function. 2. subjects with a psa \> 10.0 ng/ml. 3. subjects with a history of prostate cancer. 4. subject participated in another investigational agent study in the past 30 days or is planning to do so during the study period. 5. subjects are considered ineligible for the study as judged by the investigator.
comparison of overlap and end-to-end repair in anal sphincter rupture during delivery

Conditions: Rupture; Childbirth

Summary: rupture of the external anal sphincter occurs in about 4% percent of deliveries. it is not clear from other studies whether the results concerning anal function, e.g. fecal continence, are better with the overlap repair or end-to-end repair of the injured muscle. the researchers randomize women at birth to either overlap or end-to-end when the injury is recognized, and examine them one year later with special anal physiologic examinations and a validated questionnaire. the hypothesis is that the overlap technique is superior.

rupture of the external anal sphincter occurs in about 4% percent of deliveries in our department. it is not clear from other studies whether the results concerning anal function are better with the overlap repair or end-to-end repair of the injured muscle. our routine has been to perform an end-to-end repair, though anal surgeons, in the setting of a secondary repair, prefer the overlap method. former studies, when the repair was performed by highly skilled operators, have indicated that the overlap method is better. we wanted to compare the two methods through a rct with the end-points examination results after one year addressing endoanal sonography findings, anal manometric results and continence score evaluated by a weksner score questionnaire. our study is performed in the routine clinical setting. the patients are recruited to the study during delivery when the injury is recognized. when she has given her informed consent she is randomized to one of the two operation methods. the operation is performed by the consultant obstetrician on call or the resident supervised by the consultant. the proctologist who performs the anal manometry and sonography after one year is blinded to the surgical method. we plan to include approximately 160 patients at one center. in our center we have about 4500 deliveries per year.

Eligibility criteria:
inclusion criteria: * delivery * anal sphincter rupture exclusion criteria: * lack of ability to understand the informed consent form * lack of ability to cooperate

Keywords: anal sphincter delivery primary repair end-to-end repair over-lap repair anal manometry anal sonography weksner score rupture of the external anal sphincter during delivery anal sphincter anal sphincter rupture
the effect of aerobic exercise training for migraine prevention.

Conditions: Headache Disorders, Primary

Summary: this study has been designed in order to know the effect of 12 weeks of aerobic exercise training for migraine prevention. we hypothesized that the exercise training could reduce the number of days with migraine and the number of attacks per month in the treated group.

the study will cover 20 weeks. the first 8 weeks has been designed as "baseline" period, to assess the migraine status and classification, colect blood exam, perform a cardiopulmonary exercise test to determine the maximal oxygen uptake, and fill psychometric questionnaires. the remaining 12 weeks will be the "intervention" period, where participants after randomization will be allocated to perform an aerobic exercise training (on treadmill) performed on a 3 times per week-based program of 40-min duration each session, or will wait for the equal period to repeat all the assessments, then begin the same exercise protocol.

Eligibility criteria:
inclusion criteria: * sedentary (\> 6 month) healthy subjects and sedentary (\> 6 month)subjects with migraine without aura, migraine with aura and chronic migraine; exclusion criteria: * physically active(\> 1 day/week); * tobacco user; * alcohol or abuse drug user; * taking any prescribed medication or, in the case of medication for migraine prevention, if taking \< 6 months. * having any cardiovascular, pulmonary, endocrine-metabolic, rheumatic or other neurologic disease or psychiatric disorder such as bipolar disorder and post-traumatic stress disorder. * undergoing surgical procedure less than 3 months before entering the study.

Keywords: migraine, aerobic exercise, prevention
post approval study of the cypass system

Conditions: Primary Open-angle Glaucoma; Cataract

Summary: the purpose of this study is to demonstrate that the rate of clinically relevant complications associated with cypass micro-stent placement and stability using the cypass 241-s applier, as determined at 36 months in the postmarket setting, is less than the pre-specified performance target, which is based on experience with the cypass model e applier in compass trial tmi-09-01 (nct01085357).

each subject's expected participation in the study is up to 37.5 months which includes up to 42 days between the screening and surgery visits, and 36 months of post-surgery follow-up. only one eye per subject will be implanted.

Eligibility criteria:
inclusion criteria: * able to understand the requirements of the study and willing to follow study instructions, provide written informed consent, and agree to comply with all study requirements, including the required study follow-up visits * diagnosis of primary open angle glaucoma (poag) * medicated intraocular pressure (iop) of ≥10 millimeters mercury (mmhg) and ≤25 mmhg, or an unmedicated iop of ≥21 mmhg and ≤33 mmhg * an operable age-related cataract eligible for phacoemulsification * visual acuity as specified in the protocol * other protocol-specified inclusion criteria may apply. exclusion criteria: * inability to complete a visual field test prior to surgery * use of ocular hypotensive medication/s, as specified in the protocol * diagnosis of glaucoma other than poag, as specified in the protocol * other medical conditions, as specified in the protocol * proliferative diabetic retinopathy * previous surgery for retinal detachment * previous corneal surgery * wet age-related macular degeneration * poor vision in the non-study eye not due to cataract * significant ocular inflammation or infection within 30 days of screening visit * uncontrolled systemic diseases that may put the subject's health at risk and/or prevent the subject from completing all study visits * women who are pregnant or nursing * other protocol-specified exclusion criteria may apply.

Keywords: cypass micro-stent
a comparative study of asp1585 in chronic kidney disease patients with hyperphosphatemia on hemodialysis

Conditions: Chronic Kidney Disease; Renal Dialysis; Renal Insufficiency

Summary: this is a multi-center, open-labeled study to examine the non-inferiority of asp1585 to sevelamer hydrochloride in chronic kidney disease patients with hyperphosphatemia on hemodialysis.


Eligibility criteria:
inclusion criteria: * chronic kidney disease patients on hemodialysis * hyperphosphatemia * patients on a phosphate binder or phosphate lowering drug for 28 days or longer, and that, those for whom the dose has not been changed within 28 days * written informed consent exclusion criteria: * patients with gastrointestinal surgery or enterectomy * patients with severe cardiac diseases * patients with severe constipation or diarrhea * patients with a history or complication of malignant tumors * patients with uncontrolled hypertension * patients treated with parathyroid intervention

Keywords: hyperphosphatemia hemodialysis ckd asp1585
airway clearance for prevention of chronic obstructive pulmonary disease (copd) exacerbation

Conditions: COPD; Chronic Bronchitis; Emphysema

Summary: the purpose of this study is to show that one form of mechanical airway clearance techniques, high frequency chest wall oscillation (hfcwo)using a pneumatic vest, will diminish exacerbations of copd which will improve respiratory health status.

approximately 60 to 70% of people with copd have chronic cough and phlegm, the cardinal symptoms of chronic bronchitis or chronic mucus hypersecretion (cmh). once thought to be a relatively benign condition, recent evidence shows that cmh in patients with established copd is associated with greater decline in lung function, more frequent respiratory infections, more frequent exacerbations and increased mortality.using mechanical airway clearance techniques (the vest) will diminish exacerbations of copd which will improve respiratory health status. comparison: patients randomly assigned to the vest will have fewer exacerbations of copd,better quality of life and less health care use compared to patients assigned to a sham vest.

Eligibility criteria:
inclusion criteria: * physician diagnosis of copd,chronic bronchitis and/or emphysema * forced expiratory volume in 1 second (fev1)/ forced vital capacity (fvc) \< or = 70% * fev1 \< or = 65% * current or former smoker \> or = 20 pack years * history of 1 or more copd exacerbations in past 6 months necessitation hospitalization, emergency department (ed) visit, antibiotic or steroid prescription exclusion criteria: * other lung diseases * co-morbid illnesses such as cancer, liver disease, cardiomyopathy * recent chest wall or abdominal trauma or surgery that would preclude using the vest

Keywords: copd
incidence and predictive factor of irritable bowel syndrome after acute diverticulitis in korea

Conditions: Diverticulitis and Irritable Bowel Syndrome

Summary: the pathogenesis of irritable bowel syndrome (ibs) is considered immune reaction of gastrointestinal tract. therefore there is growing evidence that ibs could occur after gastroenteritis. however, little is known about the incidence of ibs after acute diverticulitis. we thought that post diverticulitis status could induce ibs because diverticulitis was also bowel inflammatory disorder. this survey was designed to identify incidence of post-diverticulitis ibs and risk factor in korea.


Eligibility criteria:
inclusion criteria: * 20 years or over * patients who diagnosed diverticulitis by ct scan from 2006 to 2010 (case) * patients who admitted to hospital because of non-gastrointestinal disorder (control) exclusion criteria: * patients who diagnosed ibs before diverticulitis (case) * patients who diagnosed ibs before admission (control) * patients with bowel resection surgery except for laparoscopic appendectomy * pregnancy * do not agree the consent of this study * patients who dose not understand telephone survey such as foreigner, mental retardation.
a study of ly3305677 compared with placebo in adult participants with obesity or overweight

Conditions: Obesity; Overweight and Obesity

Summary: the main purpose of this study, performed under a master protocol w8m-mc-cwmm (nct06143956), is to investigate weight management efficacy and safety with ly3305677 compared with placebo and in adult participants with obesity or overweight. the study will last about 62 weeks.


Eligibility criteria:
inclusion criteria: w8m-mc-oxa1: * are males and females who agree to abide by the reproductive and contraceptive requirements w8m-mc-cwmm: * have a bmi ≥27 kilograms per square meter (kg/m²) exclusion criteria: w8m-mc-oxa1: * have any prior diagnosis of diabetes mellitus, that is type 2 diabetes mellitus (t2dm), or rare forms of diabetes mellitus, except gestational diabetes. * have any of the following cardiovascular conditions within 6 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure (chf). * have a history of acute or chronic pancreatitis. * have a history of new york heart association (nyha) functional classification i-iv chf. * participants with hypertension who do not have well-controlled blood pressure (bp) (\>140/90 mmhg), regardless of antihypertensive treatment. participants receiving treatment for hypertension should be on a stable antihypertensive regimen for at least 3 months prior to screening. note: if the investigator anticipates a need to add antihypertensive medication during the study, the participant should not be included in the ambulatory blood pressure monitoring (abpm) procedures. cwmm: * have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening. * have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma. * have poorly controlled hypertension. * have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease. * have a history of symptomatic gallbladder disease within the past 2 years. * have a lifetime history of suicide attempts.

Keywords: incretins weight loss overnutrition
luteolin for the treatment of people with schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: luteolin is a natural product found in foods such as celery, green pepper, parsley, and chamomile tea. it has been found to have anti-cancer, anti-oxidant, and anti-inflammatory properties. the purpose of this study is to determine if luteolin helps improve symptoms of schizophrenia.

the study is a 12-week, double-blind, placebo-controlled, parallel group, randomized clinical trial of the efficacy of luteolin for the treatment of people with schizophrenia, who present with residual symptoms and cognitive impairments. the study will be conducted at two sites: the maryland psychiatric research center (mprc) and the university of california los angeles (ucla). participants will be randomized to either 300mg bid luteolin (three 100mg capsules) or placebo. we hypothesize that luteolin will have significant beneficial effects on global psychopathology and cognitive impairments; decrease antioxidant stress and levels of inflammatory markers; and that improvement in global psychopathology and cognition will be associated with changes in the oxidative stress and inflammatory measures. we also hypothesize that luteolin will be associated with improvements in positive and negative symptoms of schizophrenia.

Eligibility criteria:
inclusion criteria: * either male or female of any race * age is 18-60 years old * meets dsm-5 criteria for schizophrenia or schizoaffective disorder * positive and negative syndrome scale (panss) total score of 75 or more or a clinical global impression severity of illness item score of 4 or more * clinically stable * treated with the same antipsychotic for at least 60 days and have received a constant therapeutic dose for at least 30 days prior to study entry * able to participate in the informed consent process and provide voluntary informed consent exclusion criteria: * meets dsm-5 criteria for alcohol or substance misuse (except caffeine and nicotine) within the last 6 months; or a positive baseline urine drug screen. participants who meet dsm-5 criteria for marijuana misuse - mild will be included in the study * a current infection, including hiv and hepatitis c; or an organic brain disorder or medical condition, whose pathology or treatment could alter the presentation or treatment of schizophrenia or significantly increase the risk associated with the proposed treatment protocol * currently taking immunosuppressive medications (e.g. oral scheduled corticosteroids, chemotherapy or transplantation or hiv/aids associated drugs); or anti-inflammatory medications, including nsaids (e.g. ibuprofen, celecoxib, or naproxen) or aspirin \> 81 mg on a daily basis. the use of prn anti-inflammatory agents will be allowed. * female participants who are pregnant or nursing
the effect of rituximab on cognitive and hand functions in secondary progressive multiple sclerosis

Conditions: Secondary Progressive Multiple Sclerosis (SPMS)

Summary: the goal of this clinical trial is to know if rituximab can improve cognitive and hand functions in secondary progressive multiple sclerosis (spms) patients with high disability (edss 6.5 or more). the main questions it aims to answer are: can rituximab improve cognitive and hand functions in spms patients? can rituximab improve the quality of life and the expanded disability status scale (edss) in spms patients? researchers will compare patients who receive rituximab to patient who receive placebo to see the effects of rituximab on cognition, hand functions, quality of life and edss. demographic and clinical data as age, gender, disease duration and edss will be obtained from each participant. participants will perform the brief international cognitive assessment for multiple sclerosis (bicams), the nine-hole peg test (9-hpt) and the ms-qlq27 questionnaire at baseline and after one year of receiving either rituximab or placebo.


Eligibility criteria:
inclusion criteria: 1. diagnosis of secondary progressive multiple sclerosis by lorscheider et al's criteria (disability progression by 1 edss step in patients with edss ≤ 5.5 or 0.5 edss step in patients with edss ≥ 6 in the absence of a relapse, a minimum edss score of 4 and pyramidal functional system (fs) score of 2 and confirmed progression over ≥3 months, including confirmation within the leading fs). 2. baseline edss ≥ 6.5. exclusion criteria: 1. patients received disease modifying therapy for spms other than rituximab. 2. clinical relapse in the last 3 months before recruitment. 3. patients with documented hypersensitivity or contraindication to rituximab. 4. patients with concomitant neurologic conditions that may affect cognitive or hand functions.

Keywords: rituximab cognitive functions hand functions secondary progressive multiple sclerosis
machine learning models for predicting unforeseen hospital admissions or discharges after anesthesia

Conditions: Anesthesia Complication; Surgery-Complications; Pain, Postoperative

Summary: unexpected hospital admissions after ambulatory surgery not only bring discomfort to patients but also causes a decrease in the efficiency of the healthcare system. in addition, unanticipated patient's orientation carry the risk of unsuitable post operative orders. the hypothesis of this project is that artificial intelligence models will outperform traditional models in predicting which patients will require hospital admission after ambulatory surgery or unforeseen hospital discharge after surgery.


Eligibility criteria:
inclusion criteria: * patient undergoing anesthesia for a therapeutic or diagnostic procedure exclusion criteria: * incomplete informatic data * error in the encoding system

Keywords: anesthesiology ambulatory surgery artificial intelligence machine learning post operative complication